Iovance Biotherapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Iovance Biotherapeutics has a total shareholder equity of $680.0M and total debt of $1,000.0K, which brings its debt-to-equity ratio to 0.1%. Its total assets and total liabilities are $869.8M and $189.8M respectively.
Key information
0.1%
Debt to equity ratio
US$1.00m
Debt
Interest coverage ratio | n/a |
Cash | US$356.20m |
Equity | US$680.02m |
Total liabilities | US$189.81m |
Total assets | US$869.83m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2LB's short term assets ($385.5M) exceed its short term liabilities ($83.2M).
Long Term Liabilities: 2LB's short term assets ($385.5M) exceed its long term liabilities ($106.6M).
Debt to Equity History and Analysis
Debt Level: 2LB has more cash than its total debt.
Reducing Debt: 2LB's debt to equity ratio has increased from 0% to 0.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2LB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 2LB has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 22.9% each year.